<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00111605</url>
  </required_header>
  <id_info>
    <org_study_id>HVTN 060</org_study_id>
    <secondary_id>10057</secondary_id>
    <nct_id>NCT00111605</nct_id>
  </id_info>
  <brief_title>Study of an HIV Preventive Vaccine Given With or Without an Adjuvant in HIV Uninfected Adults</brief_title>
  <official_title>A Phase I Clinical Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Gag DNA Vaccine With or Without IL-12 DNA Adjuvant, Boosted With Homologous Plasmids in Healthy, HIV-1 Uninfected Adult Participants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Allergy and Infectious Diseases (NIAID)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Institute of Allergy and Infectious Diseases (NIAID)</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of an experimental HIV&#xD;
      vaccine. The vaccine will be given with or without IL-12 DNA adjuvant (at three escalating&#xD;
      doses of 100, 500, and 1,500 mcg respectively), a substance that helps the body respond to a&#xD;
      vaccine. This study will also determine the safety and tolerability of an experimental HIV&#xD;
      vaccine boosted with two adjuvants.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The HIV epidemic is a major global health challenge, causing tremendous human suffering and&#xD;
      economic loss throughout the world. The need for a safe, effective, and affordable HIV&#xD;
      preventive vaccine is critical. This study will determine the safety and immunogenicity of an&#xD;
      experimental HIV vaccine, HIV-1 gag DNA, given with or without an IL-12 adjuvant and boosted&#xD;
      HIV-1 gag DNA with or without IL-12 DNA adjuvant.&#xD;
&#xD;
      This study will comprise two parts (Parts A and B). Part A will last 9 months and Part B, 15&#xD;
      months. Part A will consist of 48 participants enrolled in 4 groups. Group 1 participants&#xD;
      will be randomly assigned to receive the gag DNA vaccine or placebo. Participants in Groups&#xD;
      2, 3, and 4 will be randomly assigned to receive the gag DNA vaccine and either 100 mcg, 500&#xD;
      mcg, or 1,500 mcg IL-12 DNA or placebo. Vaccinations for Groups 1 through 4 will be given&#xD;
      intramuscularly and will occur at study entry and at Months 1 and 3.&#xD;
&#xD;
      Part B will consist of 96 participants, enrolled in 3 groups. Participants in Part B will&#xD;
      receive their first vaccination 2 weeks after Part A participants receive their second&#xD;
      vaccination. Group 5 participants will receive either the HIV-1 gag DNA vaccine or placebo.&#xD;
      Group 6 participants will receive either the HIV-1 gag DNA vaccine plus IL-12 DNA or placebo.&#xD;
      Vaccinations for Groups 5 and 6 will occur at study entry and at Months 1, 3, 6, and 9. Group&#xD;
      7 participants will receive either the gag DNA vaccine plus IL-12 DNA or placebo at study&#xD;
      entry and at Months 1 and 3. Throughout the study, blood and urine collections will occur,&#xD;
      physical exams will be conducted, HIV testing and counseling will be offered, and interviews&#xD;
      and questionnaires will be completed.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <completion_date type="Actual">May 2008</completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety, as judged by local and systemic reactogenicity signs and symptoms, laboratory measures of safety, and adverse and serious experiences</measure>
    <time_frame>Throughout the study</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity, as judged by HIV-specific cellular responses assessed by interferon-gamma ELISpot assays and by intracellular cytokine staining (ICS)</measure>
    <time_frame>Throughout the study</time_frame>
  </secondary_outcome>
  <number_of_arms>7</number_of_arms>
  <enrollment type="Actual">144</enrollment>
  <condition>HIV Infections</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV gag DNA vaccine or placebo on Days 0, 28, and 84</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV gag DNA vaccine plus 100 mcg of IL-12 or placebo on Days 0, 28, and 84</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV gag DNA vaccine plus 500 mcg of IL-12 or placebo on Days 0, 28, and 84</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV gag DNA vaccine plus 1,500 mcg of IL-12 or placebo on Days 0, 28, and 84</description>
  </arm_group>
  <arm_group>
    <arm_group_label>5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV gag DNA vaccine or placebo on Days 0, 28, 84, 168, and 273</description>
  </arm_group>
  <arm_group>
    <arm_group_label>6</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV gag DNA vaccine plus IL-12 or placebo on Days 0, 28, and 84 plus CTL MEP/RC529-SE/GM-SCF booster vaccine on Days 168 and 273</description>
  </arm_group>
  <arm_group>
    <arm_group_label>7</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>HIV gag DNA vaccine plus IL-12 DNA adjuvant or placebo on Days 0 and 84</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIV-1 gag DNA</intervention_name>
    <description>A 0.75 mL intramuscular injection of HIV gag DNA vaccine into the deltoid</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HIV-1 gag DNA plus IL-12 DNA adjuvant</intervention_name>
    <description>Injection IL-12 DNA adjuvant intramuscularly into the deltoid</description>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>CTL MEP/RC529-SE/GM-CSF (CTL MEP vaccine)</intervention_name>
    <description>A 1 mL intramuscular injection in the deltoid</description>
    <arm_group_label>6</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Sodium chloride injection (0.9%)</intervention_name>
    <description>All placebo groups will receive an intramuscular injection of sodium chloride (0.9%) in the deltoid.&#xD;
Group 1 will receive a 0.75 mL injection on Days 0, 28, and 84. Group 2 will receive a 0.8 mL injection on Days 0, 28, and 84. Group 3 will receive a 1.0 mL injection on Days 0, 28, and 84. Group 4 will receive a 1.5 mL injection on Days 0, 28, and 84. Group 5 will receive a 0.75 mL injection on Days 0, 28, 84, 168, and 273. Group 6 will receive a 1.5 mL injection on Days 0, 28, 84, 168, and 273. Group 7 will receive a 1.5 mL injection on Days 0, 28, and 84 and a 1 mL injection into the deltoid on Days 168 and 273.</description>
    <arm_group_label>1</arm_group_label>
    <arm_group_label>2</arm_group_label>
    <arm_group_label>3</arm_group_label>
    <arm_group_label>4</arm_group_label>
    <arm_group_label>5</arm_group_label>
    <arm_group_label>6</arm_group_label>
    <arm_group_label>7</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  HIV uninfected&#xD;
&#xD;
          -  Access to a participating HIV Vaccine Trials Unit (HVTU)&#xD;
&#xD;
          -  Willing to receive HIV test results&#xD;
&#xD;
          -  Willing and able to comply with all study requirements&#xD;
&#xD;
          -  In good general health&#xD;
&#xD;
          -  Willing to use acceptable methods of contraception for at least 21 days prior to study&#xD;
             entry and until the last study visit. More information about this criterion can be&#xD;
             found in the protocol.&#xD;
&#xD;
          -  Hepatitis B surface antigen negative&#xD;
&#xD;
          -  Anti-hepatitis C virus (anti-HCV) antibody negative or negative HCV PCR if anti-HCV&#xD;
             antibody is positive&#xD;
&#xD;
          -  Weighs of or greater than 110 pounds (50 kg)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  HIV infection&#xD;
&#xD;
          -  HIV vaccines or placebos in prior HIV trial&#xD;
&#xD;
          -  Immunosuppressive medications within 168 days prior to first study vaccination&#xD;
&#xD;
          -  Blood products within 120 days prior to first study vaccination&#xD;
&#xD;
          -  Live attenuated vaccines within 30 days prior to first study vaccination&#xD;
&#xD;
          -  Medically indicated subunit or killed vaccines within 14 days prior to first study&#xD;
             vaccination&#xD;
&#xD;
          -  Pneumococcal vaccine within 14 days prior to first study vaccination&#xD;
&#xD;
          -  Allergy treatment with antigen injections within 30 days prior to first study&#xD;
             vaccination&#xD;
&#xD;
          -  Current anti-tuberculosis (TB) preventive therapy or treatment&#xD;
&#xD;
          -  Clinically significant medical condition, abnormal physical exam findings, abnormal&#xD;
             laboratory results, or past medical history that may affect current health&#xD;
&#xD;
          -  Any medical, psychiatric, or social condition that would interfere with the study.&#xD;
             More information about this criterion can be found in the protocol.&#xD;
&#xD;
          -  Any job-related responsibility that would interfere with the study&#xD;
&#xD;
          -  Allergies to local amide-type anesthetics&#xD;
&#xD;
          -  Serious adverse reactions to vaccines, including hypersensitivity and related&#xD;
             symptoms. A person who had an adverse reaction to pertussis vaccine as a child is not&#xD;
             excluded.&#xD;
&#xD;
          -  Autoimmune disease or immunodeficiency&#xD;
&#xD;
          -  Active syphilis infection. Participants who have been fully treated for syphilis over&#xD;
             6 months prior to study entry are not excluded.&#xD;
&#xD;
          -  Moderate to severe asthma. More information on this criterion can be found in the&#xD;
             protocol.&#xD;
&#xD;
          -  Type 1 or type 2 diabetes mellitus. Participants with histories of isolated&#xD;
             gestational diabetes are not excluded.&#xD;
&#xD;
          -  Thyroid disease or surgical removal of the thyroid requiring medication during the 12&#xD;
             months prior to study entry&#xD;
&#xD;
          -  Accumulation of fluid in the blood vessels (angioedema) within 3 years prior to study&#xD;
             entry, with episodes requiring medication in the 2 years prior to study entry&#xD;
&#xD;
          -  Hypertension that is not well controlled by medication OR blood pressure of 150/100 or&#xD;
             higher at study entry&#xD;
&#xD;
          -  Body mass index (BMI) of 40 or greater OR BMI of 35 or greater, if certain criteria&#xD;
             are met. More information about these criteria can be found in the protocol.&#xD;
&#xD;
          -  Bleeding disorder&#xD;
&#xD;
          -  Cancer. Participants with surgically removed cancer that, in the opinion of the&#xD;
             investigator, is unlikely to recur are not excluded.&#xD;
&#xD;
          -  Absence of the spleen&#xD;
&#xD;
          -  Plans to become pregnant during the study&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
        Exclusion Criterion for Participants in Part B:&#xD;
&#xD;
          -  Allergies to yeast-derived products&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Spyros Kalams, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Scott Parker, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University of Alabama at Birmingham</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Alabama Vaccine CRS</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-2041</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Project Brave HIV Vaccine CRS</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt Vaccine CRS</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiang Mai Univ. HVTN CRS</name>
      <address>
        <city>Chiang Mai</city>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://aidsinfo.nih.gov/ContentFiles/HIVPreventionVaccines_FS_en.pdf</url>
    <description>Click here for more information about HIV preventive vaccines</description>
  </link>
  <reference>
    <citation>Bolesta E, Gzyl J, Wierzbicki A, Kmieciak D, Kowalczyk A, Kaneko Y, Srinivasan A, Kozbor D. Clustered epitopes within the Gag-Pol fusion protein DNA vaccine enhance immune responses and protection against challenge with recombinant vaccinia viruses expressing HIV-1 Gag and Pol antigens. Virology. 2005 Feb 20;332(2):467-79. Erratum in: Virology. 2005 May 10;335(2):291.</citation>
    <PMID>15680412</PMID>
  </reference>
  <reference>
    <citation>Letvin NL. Progress toward an HIV vaccine. Annu Rev Med. 2005;56:213-23. Review.</citation>
    <PMID>15660510</PMID>
  </reference>
  <reference>
    <citation>Sha BE, Onorato M, Bartlett JA, Bosch RJ, Aga E, Nokta M, Adams EM, Li XD, Eldridge J, Pollard RB. Safety and immunogenicity of a polyvalent peptide C4-V3 HIV vaccine in conjunction with IL-12. AIDS. 2004 May 21;18(8):1203-6.</citation>
    <PMID>15166537</PMID>
  </reference>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>May 23, 2005</study_first_submitted>
  <study_first_submitted_qc>May 23, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 24, 2005</study_first_posted>
  <last_update_submitted>October 13, 2021</last_update_submitted>
  <last_update_submitted_qc>October 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>AIDS Vaccines</keyword>
  <keyword>HIV Vaccines</keyword>
  <keyword>HIV Preventive Vaccine</keyword>
  <keyword>HIV Seronegativity</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

